EXHIBIT 10.34 JOINT DEVELOPMENT AND LICENSE AGREEMENT BY AND BETWEEN LG LIFE SCIENCES, LTD.Joint Development and License Agreement • August 16th, 2004 • Anadys Pharmaceuticals Inc • Pharmaceutical preparations
EXHIBIT 10.8.1 [XXXXXX]=CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED PURSUANT TO AN ORDER GRANTING CONFIDENTIAL TREATMENT ISSUED BY THE SECURITIES AND EXCHANGE COMMISSION. JOINT DEVELOPMENT AND LICENSE AGREEMENT This JOINT DEVELOPMENT AND...Joint Development and License Agreement • March 11th, 1999 • Mips Technologies Inc • Semiconductors & related devices • California
EX-10.6 10 d576774dex106.htm EX-10.6 CONFIDENTIAL EXECUTION COPY JOINT DEVELOPMENT & LICENSE AGREEMENTJoint Development and License Agreement • May 5th, 2020 • England and Wales
This Joint Development and License Agreement (this “Agreement”) is made as of the 31st day of December 2012 (the “Effective Date”), by and between Pfenex, Inc., a Delaware corporation with a principal place of business located at 10790 Roselle Street, San Diego, CA 92121 (“Pfenex”), and Agila Biotech Private Limited, company incorporated under the Companies Act, 1956 and having its registered office at Strides House, Bilekahalli, Bannerghatta Road, Bangalore 560 076, India (“Agila”). Pfenex and Agila may be referred to individually as a “Party” or together as the “Parties.”
ALSO BEEN PROVIDED TO THE SECURITIES AND EXCHANGE COMMISSION. JOINT DEVELOPMENT AND LICENSE AGREEMENTJoint Development and License Agreement • July 13th, 2016 • AzurRx BioPharma, Inc. • Pharmaceutical preparations
EX-10.8 9 dex108.htm JOINT DEVELOPMENT AND LICENSE AGREEEMENT EXECUTION COPY JOINT DEVELOPMENT AND LICENSE AGREEMENTJoint Development and License Agreement • May 5th, 2020 • New York
THIS JOINT DEVELOPMENT AND LICENSE AGREEMENT (the “JDA” or “Agreement”) is made by and among BP BIOFUELS NORTH AMERICA LLC, a Delaware limited liability company (“BP”), with a principal place of business at 28100 Torch Parkway, Warrenville, IL 60555, VERENIUM BIOFUELS CORPORATION, a Delaware corporation (“Verenium”), with a principal place of business at 55 Cambridge Parkway, Cambridge, MA 02142, and GALAXY BIOFUELS LLC, a Delaware limited liability company (“SPE”), with a principal place of business at 28100 Torch Parkway, Warrenville, IL 60555, and is effective as of the Effective Date.
JOINT DEVELOPMENT AND LICENSE AGREEMENTJoint Development and License Agreement • July 27th, 2015 • NantKwest, Inc. • Biological products, (no disgnostic substances) • Delaware
This Joint Development and License Agreement (this “Agreement”) is made and entered into as of the 18th day of December, 2014 (the “Effective Date”), by and between CONKWEST INCORPORATED, a Delaware corporation with offices at 2533 South Coast Highway 101, Suite 210, Cardiff-By-The-Sea, CA 92007-2133 (“CONKWEST”), and SORRENTO THERAPEUTICS, INC., a Delaware corporation with offices at 6042 Cornerstone Ct. W., San Diego, Ca 92121 (“SRNE”). CONKWEST and SRNE are sometimes referred to herein individually as a “Party” and together as the “Parties.”
EX-99.1 3 dex991.htm THIRD EXTENSION AGREEMENT TO JOINT DEVELOPMENT AND LICENSE AGREEMENT EXECUTION VERSION THIRD EXTENSION AGREEMENT TO JOINT DEVELOPMENT AND LICENSE AGREEMENTJoint Development and License Agreement • May 5th, 2020 • New York
THIS THIRD EXTENSION AGREEMENT TO JOINT DEVELOPMENT AND LICENSE AGREEMENT (this “Third Extension”) is entered into as of July 14, 2010, by and among BP Biofuels North America LLC, a Delaware limited liability company (“BP”), Verenium Biofuels Corporation, a Delaware corporation (“Verenium”), and Galaxy Biofuels LLC, a Delaware limited liability company (“Galaxy”), each of which is referred to herein individually as a “Party,” and collectively as the “Parties.”
RECITALSJoint Development and License Agreement • October 28th, 1999 • Sage Inc/Ca • Electronic components, nec • California
EXHIBIT 10.7.4 FOURTH ADDENDUM TO JOINT DEVELOPMENT AND LICENSE AGREEMENT Nintendo Co., Lt. ("NCL"), Nintendo of America Inc. ("NOA") (NCL and NOA are referred to collectively as "Company"); and Silicon Graphics, Inc. and MIPS Technologies, Inc....Joint Development and License Agreement • June 26th, 1998 • Mips Technologies Inc • Electronic computers
ALSO BEEN PROVIDED TO THE SECURITIES AND EXCHANGE COMMISSION. JOINT DEVELOPMENT AND LICENSE AGREEMENTJoint Development and License Agreement • October 16th, 2015 • AzurRx BioPharma, Inc. • Pharmaceutical preparations
JOINT DEVELOPMENT AND LICENSE AGREEMENTJoint Development and License Agreement • January 29th, 2014 • AMEDICA Corp • Surgical & medical instruments & apparatus • Utah
This Joint Development Agreement (the “Agreement”) entered into as of the 8th day of February, 2010 (the “Effective Date”) is by and between Amedica Corporation, a Delaware corporation with a principal place of business at 1885 West 2100 South, Salt Lake, City, Utah 84119 (“Amedica”) and Orthopaedic Synergy, Inc., a Delaware corporation with a principal place of business at 50 O’Connell Way #10, East Taunton, MA 02718 (“OSI”). Amedica and OSI are each referred to herein as a “Party” and collectively as “Parties”.
JOINT DEVELOPMENT & LICENSE AGREEMENTJoint Development and License Agreement • March 30th, 2015 • Pieris Pharmaceuticals, Inc. • Services-commercial physical & biological research • England and Wales
This Joint Development and License Agreement (this “Agreement”) is made as of November 21st, 2013 (the “Effective Date”), by and between Pieris AG, a German stock corporation organized and existing under the laws of Germany, whose principal place of business is at Lise-Meitner-Straße 30, 85354 Freising, Germany (“Pieris”), and Stelis BioPharma Private Limited, formerly known as Agila Biotech Private Limited, a company incorporated under the Companies Act (India), 1956 and having its registered office at Strides House, Bilekahalli, Bannerghatta Road, Bangalore 560 076, India (“Stelis BioPharma”). Pieris and Stelis BioPharma may be referred to individually as a “Party” or together as the “Parties.”
Sumitomo Dainippon Pharma and SanBio Conclude Joint Development and License Agreement for North AmericaJoint Development and License Agreement • September 23rd, 2014
Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; President: Masayo Tada) (“Sumitomo Dainippon Pharma”) and SanBio Co., Ltd. (Head Office: Chuo-ku, Tokyo, Japan; President: Keita Mori), acting through its U.S. subsidiary SanBio, Inc. (Head Office: Mountain View, California, USA) (“SanBio”), announced today that the two companies have entered into a joint development and license agreement for exclusive marketing rights in the
JOINT DEVELOPMENT & LICENSE AGREEMENTJoint Development and License Agreement • December 18th, 2014 • Marika Inc. • Services-business services, nec • England and Wales
This Joint Development and License Agreement (this “Agreement”) is made as of November 21st, 2013 (the “Effective Date”), by and between Pieris AG, a German stock corporation organized and existing under the laws of Germany, whose principal place of business is at Lise-Meitner-Straße 30, 85354 Freising, Germany (“Pieris”), and Stelis BioPharma Private Limited, formerly known as Agila Biotech Private Limited, a company incorporated under the Companies Act (India), 1956 and having its registered office at Strides House, Bilekahalli, Bannerghatta Road, Bangalore 560 076, India (“Stelis BioPharma”). Pieris and Stelis BioPharma may be referred to individually as a “Party” or together as the “Parties.”
SECOND EXTENSION AGREEMENT TO JOINT DEVELOPMENT AND LICENSE AGREEMENTJoint Development and License Agreement • April 1st, 2010 • Verenium Corp • Industrial organic chemicals • New York
This SECOND EXTENSION AGREEMENT TO JOINT DEVELOPMENT AND LICENSE AGREEMENT (the “Second Extension”) is entered into as of March 31, 2010, by and among BP Biofuels North America LLC, a Delaware limited liability company (“BP”), Verenium Biofuels Corporation, a Delaware corporation (“Verenium”), and Galaxy Biofuels LLC, a Delaware limited liability company (“Galaxy”), each of which is referred to herein individually as a “Party,” and collectively as the “Parties.”
JOINT DEVELOPMENT AND LICENSE AGREEMENTJoint Development and License Agreement • October 22nd, 2003 • Md Technologies Inc
This Joint Development and License Agreement (the “Agreement”) is made as of this 13th day of December, 2000 (the “Effective Date”), by and among Emory University, a Georgia non-profit corporation, through its Robert W. Woodruff Health Sciences Center (the “University”), Emory Healthcare, Inc., a Georgia non-profit corporation (“Emory Healthcare”; collectively, the University and Emory Healthcare are referred to in this agreement as “Emory”), and MD Technologies, Inc., a Delaware business corporation (“MDT”).
AMENDMENT NO. 1 TO JOINT DEVELOPMENT AND LICENSE AGREEMENTJoint Development and License Agreement • February 1st, 2010 • Verenium Corp • Industrial organic chemicals • New York
This AMENDMENT NO. 1 TO JOINT DEVELOPMENT AND LICENSE AGREEMENT (the “Amendment”) is entered into as of January 31, 2010, by and among BP Biofuels North America LLC, a Delaware limited liability company (“BP”), Verenium Biofuels Corporation, a Delaware corporation (“Verenium”), and Galaxy Biofuels LLC, a Delaware limited liability company (“Galaxy”), each of which is referred to herein individually as a “Party,” and collectively as the “Parties.”
Dyax Corp. has requested that portions of this document be accorded confidential treatment pursuant to Rule 24b-2 promulgated under the Securities Exchange Act of 1934, as amended. FIFTH AMENDMENT TO JOINT DEVELOPMENT AND LICENSE AGREEMENTJoint Development and License Agreement • August 2nd, 2012 • Dyax Corp • Services-commercial physical & biological research
This FIFTH AMENDMENT (the "Fifth Amendment"), dated as of June 21, 2012 (the "Fifth Amendment Date"), is entered into by and between Dyax Corp. ("Dyax"), and Sigma Tau Rare Diseases S.A. as successor-in-interest to Defiante Farmacêutica S.A. ("STRD"). This Fifth Amendment further amends that certain Joint Development and License Agreement (the "Original Agreement"), dated effective as of June 18, 2010 (the "Effective Date"), as amended by the First Amendment to Joint Development and License Agreement (the "First Amendment”), dated December 21, 2010 (the "First Amendment Date"), the Second Amendment to Joint Development and License Agreement (the "Second Amendment"), dated May 21, 2011 (the "Second Amendment Date"), the Third Amendment to Joint Development and License Agreement (the "Third Amendment"), dated December 26, 2011 (the "Third Amendment Date") and Fourth Amendment to Joint Development and License Agreement (the "Fourth Amendment"), dated May 29, 2012 (the "Fourth Amendment Da
THIRD AMENDMENT TO JOINT DEVELOPMENT AND LICENSE AGREEMENTJoint Development and License Agreement • March 2nd, 2012 • Dyax Corp • Services-commercial physical & biological research
This THIRD AMENDMENT (the "Third Amendment"), dated as of December 26, 2011 (the "Third Amendment Date"), is entered into by and between Dyax Corp., with effective offices at 300 Technology Square, Cambridge, Massachusetts 02139, U.S.A. ("Dyax"), and DefianteFarmacêutica S.A., with registered offices at Rua da Alfândega, n. 78, 3° andar, 9000-059, Funchal, Madeira, Portugal ("Defiante"). This Third Amendment further amends that certain Joint Development and License Agreement (the "Original Agreement"), dated effective as of June 18, 2010 (the "Effective Date"), as amended by the First Amendment to Joint Development and License Agreement (the "First Amendment”), dated December 21, 2010 (the "First Amendment Date") and the Second Amendment to Joint Development and License Agreement (the "Second Amendment"), dated May 21, 2011 (the "Second Amendment Date"). The Original Agreement, as amended by the First Amendment and the Second Amendment, is referred to herein as the "Amended Agreement."
ContractJoint Development and License Agreement • November 2nd, 2007 • Palomar Medical Technologies Inc • Electromedical & electrotherapeutic apparatus
Third Amendment to the September 7, 2004 Joint Development and License Agreement Between Palomar Medical Technologies, Inc. and Johnson & Johnson Consumer Companies, Inc. (the “Agreement”) Whereas, pursuant to the Agreement, the parties are engaged in a collaboration to develop, clinically test and potentially commercialize home-use, light-based devices for (i) reducing or reshaping body fat including cellulite; (ii) reducing appearance of skin aging; and (iii) reducing or preventing acne; and Whereas, the parties desire to **. Now, Therefore, in consideration of the foregoing premises, the mutual promises and covenants of the parties contained herein, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto, intending to be legally bound, do hereby agree as follows effective this 15th day of August 2007: 1. **.
JOINT DEVELOPMENT AND LICENSE AGREEMENTJoint Development and License Agreement • May 18th, 2023 • Vast Solar Pty LTD • Electric services • Texas
This Joint Development and License Agreement (the “Agreement”) is entered into as of February 14, 2023 (“Effective Date”) by and between Nabors Energy Transition Ventures LLC, a Delaware limited liability company having a place of business at 515 W. Greens Road, Suite 1200, Houston TX 77067, together with its direct and indirect Affiliates (as defined below) (collectively, “Nabors”), and Vast Solar Pty Ltd., a company formed under the laws of Australia, having a place of business at 226-288 Liverpool Street, Darlinghurst NSW 2010 Australia, together with its direct and indirect Affiliates (as defined below) (collectively, “Vast”), each referred to herein as a “Party” and collectively as the “Parties”.
ContractJoint Development and License Agreement • May 8th, 2007 • Palomar Medical Technologies Inc • Electromedical & electrotherapeutic apparatus
Second Amendment to the September 7, 2004 Joint Development and License Agreement Between Palomar MedicalTechnologies, Inc. and Johnson & Johnson Consumer Companies, Inc. (the “Agreement”) Whereas, pursuant to the Agreement, the parties are engaged in a collaboration to develop, clinically test and potentially commercialize home-use, light-based devices for (i) reducing or reshaping body fat including cellulite; (ii) reducing appearance of skin aging; and (iii) reducing or preventing acne; and Whereas, the parties desire to modify certain provisions of the Agreement in order to **. Now, Therefore, in consideration of the foregoing premises, the mutual promises and covenants of the parties contained herein, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto, intending to be legally bound, do hereby agree as follows effective on the 1st day of April 2007: 1. Appendix E to the Agreement is hereby amended to include ne
Sumitomo Dainippon Pharma and SanBio Conclude Joint Development and License Agreement for North AmericaJoint Development and License Agreement • September 29th, 2014
Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; President: Masayo Tada) (“Sumitomo Dainippon Pharma”) and SanBio Co., Ltd. (Head Office: Minato-ku, Tokyo, Japan; President: Keita Mori), acting through its U.S. subsidiary SanBio, Inc. (Head Office: Mountain View, California, USA) (“SanBio”), announced today that the two companies have entered into a joint development and license agreement for exclusive marketing rights in the
Exhibit 99(c)(7) EXECUTION COPY JOINT DEVELOPMENT AND LICENSE AGREEMENT This LICENSE AGREEMENT is made and effective as of March 18, 1998 ("Effective Date") by and between MOTOROLA, INC., a Delaware corporation ("Motorola"), having a principal place...Joint Development and License Agreement • March 25th, 1998 • Motorola Inc • Radio & tv broadcasting & communications equipment • Illinois
BACKGROUNDJoint Development and License Agreement • March 11th, 1999 • Mips Technologies Inc • Semiconductors & related devices
JOINT DEVELOPMENT AND LICENSE AGREEMENTJoint Development and License Agreement • December 28th, 2023 • Alto Neuroscience, Inc. • Pharmaceutical preparations • New York
This JOINT DEVELOPMENT AND LICENSE AGREEMENT (this “Agreement”) is made and entered into as of September 25, 2023 (the “Effective Date”) by and between MEDRX CO., LTD., a Japanese corporation, having offices at 431-7 Nishiyama Higashikagawa-city, Kagawa, Japan769-2712 (“MedRx”), and ALTO NEUROSCIENCE, INC., a Delaware corporation, with a principal office at 369 South San Antonio Road, Los Altos, California 94022, USA (“Licensee”). MedRx and Licensee are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
TRANSLATION Basic Contract on Joint Development and Grant of LicenseJoint Development and License Agreement • December 26th, 2007 • Magnachip Semiconductor LLC • Semiconductors & related devices
This Basic Contract on Joint Development and Grant of License (hereinafter “Contract”) is made and entered into as of November 10, 2006, by between MagnaChip Semiconductor, Ltd. (hereinafter “MC”) and Silicon Works Co., Ltd. (hereinafter “SW”).
Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote such omission. FIRST AMENDMENT TO JOINT DEVELOPMENT AND LICENSE AGREEMENTJoint Development and License Agreement • March 2nd, 2011 • Dyax Corp • Services-commercial physical & biological research
This FIRST AMENDMENT (the “First Amendment”), dated as of December 21, 2010 (the “Amendment Date”), is entered into by and between Dyax Corp., with principal offices at 300 Technology Square, Cambridge, Massachusetts 02139, U.S.A. (“Dyax”), and Defiante Farmacêutica S.A., with registered offices at Rua da Alfândega, n. 78, 3° andar, 9000-059, Funchal, Madeira, Portugal (“Defiante”). This First Amendment amends that certain Joint Development and License Agreement (the “Original Agreement”), dated effective as of June 18, 2010 (the “Effective Date”) by and between Dyax and Defiante. All capitalized terms not otherwise defined in this First Amendment shall be as defined in the Original Agreement.
ContractJoint Development and License Agreement • November 2nd, 2007 • Palomar Medical Technologies Inc • Electromedical & electrotherapeutic apparatus
Fourth Amendment to the September 7, 2004 Joint Development and License Agreement Between Palomar Medical Technologies, Inc. and Johnson & Johnson Consumer Companies, Inc. (the “Agreement”) Whereas, pursuant to the Agreement, the parties are engaged in a collaboration to develop, clinically test and potentially commercialize home-use, light-based devices for (i) reducing or reshaping body fat including cellulite; (ii) reducing appearance of skin aging; and (iii) reducing or preventing acne; and Whereas, the parties desire to modify certain provisions of the Agreement in order to **; and Whereas, the parties desire to modify certain provisions of the Agreement in order to Allow JJC to terminate the Agreement during the Optimization Period. Now, Therefore, in consideration of the foregoing premises, the mutual promises and covenants of the parties contained herein, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto,
Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote such omission. JOINT DEVELOPMENT AND LICENSE AGREEMENT BY AND BETWEEN DYAX CORP. AND DEFIANTE FARMACÊUTICA S.A., DATED AS OF JUNE 18, 2010Joint Development and License Agreement • August 2nd, 2010 • Dyax Corp • Services-commercial physical & biological research • Massachusetts
ContractJoint Development and License Agreement • August 8th, 2006 • Palomar Medical Technologies Inc • Electromedical & electrotherapeutic apparatus
First Amendment to the September 7, 2004 Joint Development and License Agreement Between Palomar MedicalTechnologies, Inc. and Johnson & Johnson Consumer Companies, Inc. (the “Agreement”) Whereas, pursuant to the Agreement, the parties are engaged in a collaboration to develop, clinically test and potentially commercialize home-use, light-based devices for (i) reducing or reshaping body fat including cellulite; (ii) reducing appearance of skin aging; and (iii) reducing or preventing acne; and Whereas, the parties desire to modify certain provisions of the Agreement in order to **. Now, Therefore, in consideration of the foregoing premises, the mutual promises and covenants of the parties contained herein, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto, intending to be legally bound, do hereby agree as follows effective this 1st day of May 2006: 1. Appendix E to the Agreement is hereby amended to include new Exh
TO JOINT DEVELOPMENT AND LICENSE AGREEMENTJoint Development and License Agreement • August 2nd, 2012 • Dyax Corp • Services-commercial physical & biological research
This FOURTH AMENDMENT (the "Fourth Amendment"), dated as of May 29, 2012 (the "Fourth Amendment Date"), is entered into by and between Dyax Corp. ("Dyax"), and Sigma Tau Rare Diseases S.A. as successor-in-interest to Defiante Farmacêutica S.A. ("STRD"). This Fourth Amendment further amends that certain Joint Development and License Agreement (the "Original Agreement"), dated effective as of June 18, 2010 (the "Effective Date"), as amended by the First Amendment to Joint Development and License Agreement (the "First Amendment”), dated December 21, 2010 (the "First Amendment Date"), the Second Amendment to Joint Development and License Agreement (the "Second Amendment"), dated May 21, 2011 (the "Second Amendment Date") and the Third Amendment to Joint Development and License Agreement (the "Third Amendment"), dated December 26, 2011 (the "Third Amendment Date"). The Original Agreement, as amended by the First Amendment, the Second Amendment and the Third Amendment, is referred to herein
FIRST ADDENDUM TO JOINT DEVELOPMENT AND LICENSE AGREEMENTJoint Development and License Agreement • March 11th, 1999 • Mips Technologies Inc • Semiconductors & related devices
JOINT DEVELOPMENT & LICENSE AGREEMENTJoint Development and License Agreement • June 25th, 2014 • Pfenex Inc. • Pharmaceutical preparations • England and Wales
This Joint Development and License Agreement (this “Agreement”) is made as of the 31st day of December 2012 (the “Effective Date”), by and between Pfenex, Inc., a Delaware corporation with a principal place of business located at 10790 Roselle Street, San Diego, CA 92121 (“Pfenex”), and Agila Biotech Private Limited, company incorporated under the Companies Act, 1956 and having its registered office at Strides House, Bilekahalli, Bannerghatta Road, Bangalore 560 076, India (“Agila”). Pfenex and Agila may be referred to individually as a “Party” or together as the “Parties.”
SECOND AMENDMENT TO JOINT DEVELOPMENT AND LICENSE AGREEMENTJoint Development and License Agreement • August 4th, 2011 • Dyax Corp • Services-commercial physical & biological research
This SECOND AMENDMENT (the "Second Amendment"), dated as of May 27, 2011 (the "Second Amendment Date"), is entered into by and between Dyax Corp., with principal offices at 300 Technology Square, Cambridge, Massachusetts 02139, U.S.A. ("Dyax"), and Defiante Farmacêutica S.A., with registered offices at Rua da Alfândega, n. 78, 3° andar, 9000-059, Funchal, Madeira, Portugal ("Defiante"). This Second Amendment further amends that certain Joint Development and License Agreement (the "Original Agreement"), dated effective as of June 18, 2010 (the "Effective Date") as amended by the First Amendment to Joint Development and License Agreement (the "First Amendment”), dated December 21, 2011 (the "First Amendment Date"). The Original Agreement as amended by the First Amendment, is referred to herein as the "Amended Agreement." All capitalized terms not otherwise defined in this Second Amendment shall be as defined in the Amended Agreement.
